Concepedia

Juan Jesús Augustín

JJ

Statistics

Publications

5

Citations

95

H-Index

5

Active since

1994

Affiliations

Merck KGaA, Darmstadt (Germany)(Current)

Universidad de Cantabria

Instituto de Biomedicina y Biotecnología de Cantabria

Instituto de Investigación Marqués de Valdecilla

Juan Jesús Augustín is an author at Merck KGaA, Darmstadt (Germany) specializing in medicinal chemistry, medicine, and pharmacology.

Publications per year

1994–2016

5

Publications

5

Acute and chronic anti-inflammatory properties of [2,2-dimethyl-6-(4- chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid.

Stefan Laufer, S. Tries, Juan Jesús Augustín et al. · PubMed · 1995 · 27 citations

, , +12

Gastrointestinal tolerance of [2,2-dimethyl-6-(4-chlorophenyl-7-phenyl- 2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid in the rat.

Stefan Laufer, S. Tries, Juan Jesús Augustín et al. · PubMed · 1994 · 19 citations

, , +9

General pharmacology of [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3- dihydro-1H-pyrrolizine-5-yl]-acetic acid in experimental animals.

Algate Dr, Juan Jesús Augustín, Atterson Pr et al. · PubMed · 1995 · 18 citations

, , +12

Bone Morphogenetic Protein and Activin Membrane–Bound Inhibitor, a Transforming Growth Factor β Rheostat That Controls Murine Treg Cell/Th17 Cell Differentiation and the Development of Autoimmune Arthritis by Reducing Interleukin‐2 Signaling

Jorge Postigo, Marcos Iglesias, Pilar Álvarez et al. · Arthritis & Rheumatology · 2015 · 17 citations

, , +17

Selective Impairment of TH17-Differentiation and Protection against Autoimmune Arthritis after Overexpression of BCL2A1 in T Lymphocytes

Marcos Iglesias, Juan Jesús Augustín, Pilar Álvarez et al. · PLoS ONE · 2016 · 14 citations · Full text

, , +17

1–5 of 5